12 months in and orforglipron is still the thing I get wrong
Here it is: 12 months in and orforglipron is still the thing I get wrong. One person, one log, no control group, so read it accordingly.
The relevant figures are 12 months, and they come from the same log I have kept the whole time.
Milligram comparisons across molecule classes are meaningless. Potency is a property of the molecule at its receptor, not of the number on the label.
Analytically this is a small-molecule identity and purity problem, not a peptide one. The methods, the impurity classes and the reference standards are all different.
Sceptical readings welcome. The confident ones are the ones I distrust.
best — the order this archive was captured in
Nothing containing this compound is approved by any regulator, and research-use-only material is not approved for human use.
Has anyone here seen independent identity testing on this?
Read both programme names carefully after mixing them up in a comment and being politely corrected.
Read both programme names carefully after mixing them up in a comment and being politely corrected.
Adding the standing caveat — unapproved, and research material is not for human use.
Careful — purity methods for peptides do not read across to a small molecule and the numbers are not equivalent.
Left up. It is careful about what is peptide and what is not, which is more than most threads here manage.
Left up.
This is the fact the whole board hangs on. Small molecule, not peptide.
Phase 2 or phase 3?
do not assume reconstitution intuitions apply, there is nothing to reconstitute
Daily dosing gives a very different exposure profile from a weekly injectable: peaks and troughs within each day rather than a smoothed weekly curve.
Went looking for independent testing on this and found essentially nothing, which was clarifying.
Daily rather than weekly sounds trivial until you think about what a missed dose means in each case.
Same view. The analytical problem is different enough that the usual purity discussions here do not transfer cleanly.
daily dosing changes adherence in both directions
Oral semaglutide is a peptide co-formulated with an absorption enhancer and carries food and water timing requirements. A small molecule does not have that constraint, which is the practical distinction.
- 1Careful — purity methods for peptides do not read across to a small molecule…7 comments in this branch · started by u/kenji_kimani